Vasopeptidase inhibition: A new direction in cardiovascular treatment

Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 120 mm Hg. JAMA 1967, 202:1028–1034. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213:1143–1152. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413–2446. The Joint National Committee publishes guidelines for the treatment of hypertension every 4 to 5 years. It is focused on using outcomebased studies for their recommendations. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993, 328:914–921. Perry HMJ, Bingham S, Horney A, et al.: Antihypertensive efficacy of treatment regimens used in Veterans Administration clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Hypertension 1998, 31:771–779. An interesting paper describing the efficacy of single agents in the Veterans Affairs population. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999, 17:151–183. Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762. This extremely well-done study sought to determine how low elevated systolic and diastolic blood pressures should be reduced with treatment. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Ann Intern Med 1993, 153:154–183. The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1982, 312:1429–1435. The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1991, 327:669–677. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993, 342:821–828. Ridker PM, Gaboury LL, Conlin PK, et al.: Stimulation of plasminogen activation inhibition in-vivo by infusion of angiotensin II. Circulation 1993, 87:1969–1973. Hamsten A, DeFaire V, Walldius G, et al.: Plasminogen activator inhibition in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3–9. Alderman MH, Medhavans S, Wee LO, et al.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098–1104. Ludmer PL, Selwyn AP, Shook TL, et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986, 315:1046–1051. Lon EM, Yusuf S, Jhan P, et al.: Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056–2069. Mancini GBJ, Henry GC, Macga C, et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996, 94:258–265. Oosterga M, Vours AA, Veeger NJGM, et al.: Beneficial effects on ischemia in coronary artery bypass patients: one year clinical follow up of the QUO VADIS study [abstract]. Circulation 1998, 98(suppl):3343. The Heart Outcomes Prevention Study Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramapril, on cardivascular events in high-risk patients. N Engl J Med 2000, 342:145–153. This landmark trial demonstrated that ACE inhibitors reduce the risk of both cardiovascular events and stroke in high-risk patients. The Heart Outcomes Prevention Study Evaluation Study Investigators: Effects of ramapril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICR-HOPE study. Lancet 2000, 355:253–259. Pepine CJ: Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with perserved left ventricular function. J Am Coll Cardiol 1996, 27:1048–1052. De Bold AJ, Bornstein HB, Veress AT, et al.: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Life Sci 1981, 28:89–94. Kangawa K, Matsuo H: Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide. Biochem Biophys Res Commun 1984, 118:131–139. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339:321–328. A nice overview of the NEP system. Ruschitzka F, Corti R, Noll G, et al.: A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999, 17(suppl 1):S25-S35. Chen HH, Burnett JC Jr: C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998, 32(suppl 3):S22-S28. An early classic paper on VPIs written by one of the pioneers in the field. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17(suppl 1):S37-S43. Schweitz H, Vigne P, Moinier D, et al.: A new member of the natriuretic peptide family is present in the venom of the green mamba. J Biol Chem 1992, 267:13928–13932. Maack T, Suzuki M, Almeida FA, et al.: Physiological role of silent receptors of atrial natriuretic factor. Science 1987, 238:675–678. Robl JA, Sun CQ, Stevenson J, et al.: Dual metaloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997, 40:1570–1577. Saxenhofer H, Raseli A, Weidmann P, et al.: Urodilantin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990, 259(pt 2):P832-P838. Wilkins MR, Unwin RJ, Kenny AJ: Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension. Kidney Int 1993, 43:273–285. Endros EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989, 3:145–151. Gonzalez W, Soleihac J-M, Fournie-Zaluski M-C, et al.: Characterization of neutral endopeptidase in vascular cells, modulation of vasoactive peptide levels. Eur J Pharmacol 1998, 345:323–331. Wilcox JN, Augustine A, Goeddel DV, et al.: Differential regional expression of the three natriuretic peptide receptor genes with primate tissues. Mol Cell Biol 1991, 11:3454–3462. Ando S, Rahman MA, Butler GC, et al.: Comparison of candoxtril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995, 26pt 2:1160–1166. Richards AM, Crozier JG, Espiner EA, et al.: Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 1992, 20:735–741. Bevan EG, Connell JMC, Doyle J, et al.: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992, 10:607–613. Bevan EG, Connell JMC, Doyle J, et al.: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992, 10:607–613. Richards AM, Wittert GA, Crozier IG, et al.: Chronic inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992, 71:1501–1507. Seymour AA, Swerdel JN, Abboa-Offei B: Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991, 17:456–465. Stergiou GS, Hannah JA, Bevan EG, et al.: Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients [abstract]. J Hypertens 1994, 12:1310–1311. Weber M: Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999, 12:139S-147S. Robl JA, Sun CQ, Stevenson J, et al.: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997, 40:1570–1577. A discussion of the chemistry and development of the VPIs. Trippodo NC, Robl JA, Assad MM, et al.: Effects of omapatrilat in low, normal and high renin experimental hypertension. Am J Hypertens 1998, 11:363–372. An important animal study demonstrating that VPIs are effective antihypertensive agents in low-and high-renin states. Liao W, Delaney C, Smith R, et al.: Supine mean arterial blood pressure (MAP) lowering and oral tolerance of BMS-186716, a new dual metalloprotease inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy male subjects [abstract]. Clin Pharmacol Ther 1997, 61:229. Quaschning T, d‘Uscio LV, Luscher TF: Greater endothelial protection by the vasopeptidase inhibitor omapatrilat compared to the ACE-inhibitor captopril in salt induced hypertension. J Am Coll Cardiol 2000, 35(suppl A):248. Vesterguist O, Liao W, Manning JA, et al.: Effects of BMS-1867, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase and angiotensin-converting enzyme activity in healthy men [abstract]. Clin Pharmacol Ther 1997, 61:230. Ruddy M, Guthrie R, Papademetriou V, et al.: The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: a pilot study [abstract]. Am J Hypertens 1999, 12 pt 2:125A. Zusman R, Atlas S, Kochar M, et al.: Efficacy and safety of omapatrilat, a vasopeptidase inhibitor [abstract]. Am J Hypertens 1999, 12(pt 2):125A. Rousso P, Biclin J, Nussberger J, et al.: Effects of a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase MDL 100240, on endocrine and renal function in healthy volunteers. J Hypertens 1999, 17:427–437. Black HR, Chang PI, Reeves RA, et al.: Monotherapy treatment success rate of omapatrilat, a vasopeptidase inhibitor compared with lisinopril and amlodipine in mild to moderate hypertension [abstract]. Am J Hypertens 1999, 12(pt 2):26A. Norton GR, Woodiwiss AJ, Hartford C, et al.: Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999, 12:563–571. Holzgrete HH, Arthur SR, Powell JR: Effect of vasopeptidase inhibition with omapatrilat in a canine model of tachycardia induced heart failure. J Am Coll Card 2000, 35(suppl A):234. Thomas CV, McDaniel GM, Holzgrafe HH, et al.: Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardivasc Pharmacol 1998, 32:902–912. Trippodo NC, Robl JA, Assad NM, et al.: Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS 182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995, 275:745–754. Trippodo NC, Fox M, Munticello TM, et al.: Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition [abstract]. Circulation 1998, 98:I-781. Marie C, Mosiat C, Gros C, et al.: Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysinand ACE, on survival of rats after myocardial infarction. Cardiovasc Res 1999, 41:544–553. Ikram H, McClean DR, Mehti S, et al.: Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure. J Am Coll Cardiol 1999, 33:185A. Kostis JB, Rouleau JL, Pfeffer MA, et al.: Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: evidence from the omapatrilat heart failure program. J Am Coll Cardiol 2000, 35(suppl A):240. Chen HH, Schirger JA, Chau WL, et al.: Renal response to acute neutral endopeptidase inhibition in mild and severs experimental heart failure. Circulation 2000, 100:2443–2448. Chen HH, Lainchburg JG, Harty GJ, et al.: The superior renal and humoral actions of acute dual NEP/ACE inhibition by vasopeptidase inhibitor versus ACE inhibition in experimental mild heart failure. Properties mediated via potentiation of endogenous cardiac natriuretic peptides. J Am Coll Cardiol 2000, 35(suppl A):270.